Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2010
11/09/2010US7829541 Heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium
11/09/2010US7829540 Amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium; side effect reduction; side effect reduction
11/09/2010US7829539 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
11/09/2010US7829538 Heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium
11/09/2010US7829534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
11/09/2010US7829530 Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 by conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV; treating Type II diabetes but not sufficient to suppress the immune system of the animal
11/09/2010US7829518 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant
11/09/2010US7829117 reaction product of polystyrene bound mesna (mercaptoethanesulfonic acid, sodium salt) and a sulfur-containing amino acid, preferably cysteine; chemical intermediates; anticarcinogenic agent; side effect reduction; heteroconjugate
11/09/2010US7829112 Forming two drug permeable polymeric segments, exposing to preferential drug, connecting segments, delivering drug treatment; for use in treatment of menopausal symptoms and benign ovarian secretory disorder; contraceptive
11/09/2010US7829100 vehicle comprising; a modified unsaturated oil and, optionally, a non-oxidizable oil; immediately after manufacture, composition can be administered such that the bioactive agents are released to the host on a predictable sustained basis.
11/09/2010US7829078 Drug delivery; sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery; increasing the hematocrit and/or the reticulocyte count in a mammalian subject
11/09/2010US7829077 kit comprising an IFN- alpha selected from IFN- alpha -2a, IFN- alpha -2b, IFN- alpha -5, consensus interferon, purified IFN- alpha , pegylated IFN- alpha and a pharmaceutically acceptable quantity of oncostatin M
11/09/2010US7827986 Methods for treating jaw pain
11/09/2010CA2488279C Anti-inflammatory compositions derived from chicory
11/09/2010CA2474563C Methods of inhibiting orthopoxvirus replication with nucleoside compounds
11/09/2010CA2438544C Aerosol compositions containing formoterol for delivery to the lungs via nebulization
11/09/2010CA2430828C Pharmaceutical preparation comprising an active dispersed on a matrix
11/09/2010CA2421685C Soft tablet containing high molecular weight polyethylene oxide
11/09/2010CA2420038C Devices for intraocular drug delivery
11/09/2010CA2412899C Medicinal preparations for treating sex hormone-dependent diseases
11/09/2010CA2412493C Purging of cells using viruses
11/09/2010CA2407659C Growth hormone secretagogues
11/09/2010CA2405190C Simethicone solid oral dosage form
11/09/2010CA2393487C Pharmaceutical preparation for the treatment of oncoses
11/09/2010CA2362794C Inhibitors of separase, method for identifying them and uses
11/09/2010CA2161684C Bioactive and/or targeted dendrimer conjugates
11/07/2010CA2665956A1 Combination treatment for ocular diseases
11/04/2010WO2010126982A1 Oral compositions for skin benefits
11/04/2010WO2010126857A1 Parasiticidal combinations of macrocyclic lactones and polyether antibiotics
11/04/2010WO2010126169A1 Pharmaceutical composition for preventing vascular disorders which comprises alk1 inhibitor as active ingredient
11/04/2010WO2010126124A1 Transdermal preparation
11/04/2010WO2010126036A1 Combined drug
11/04/2010WO2010125991A1 Method for control of fish parasites
11/04/2010WO2010125348A1 Prevention and treatment of sarcopenia
11/04/2010WO2010124655A1 Complex microcapsule comprising epiphyseal plate chondrocytes and preparation method and use thereof
11/04/2010WO2010061208A3 Combination comprising a quinazoline derivative and a taxane
11/04/2010US20100280107 Treating benign prostate hyperplasia with sarms
11/04/2010US20100279959 Medium-Chain Length Fatty Acids, Glycerides and Analogues as Neutrophil Survival and Activation Factors
11/04/2010US20100278997 Preparation for restenosis prevention
11/04/2010US20100278840 Methods for treating rheumatoid arthritis using il-17 antagonists
11/04/2010US20100278838 Epha2 monoclonal antibodies and methods of use thereof
11/04/2010US20100278831 Nogo Receptor-Mediated Blockade of Axonal Growth
11/04/2010US20100278803 Alzheimer's Disease Diagnosis Based on Mitogen-Activated Protein Kinase Phosphorylation
11/04/2010US20100278783 Method of Preparing Autologous Cells and Method of Use for Therapy
11/04/2010US20100278778 Method for bone marrow preservation or recovery
11/04/2010US20100278777 Method for treating deficiency in hematopoiesis
11/04/2010US20100278744 Preparation for restenosis prevention
11/04/2010US20100278736 FLT4 (VEGFR-3) as a Target for Tumor Imaging and Anti-Tumor Therapy
11/04/2010DE202010010312U1 Verbesserungen bei und bezüglich Kolonreinigungs-Zusammensetzungen Improvements in and respect Kolonreinigungs compositions
11/04/2010CA2759936A1 Oral compositions for skin benefits
11/04/2010CA2759155A1 Antiparasitic agent for fish and method of controlling proliferation of fish parasites
11/03/2010EP2246069A1 Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
11/03/2010EP2246066A1 Use of neurotoxin therapy for treatment of urologic and related disorders
11/03/2010EP2246030A1 System for pressure bathing in gas-containing mist
11/03/2010EP2245020A2 Thiazolylidine urea and amide derivatives and methods of use thereof
11/03/2010EP2244789A2 Combination of metformin and an mtp inhibitor
11/03/2010EP2244702A1 Treatment of neural diseases or conditions
11/03/2010EP2046331B1 Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
11/03/2010EP1741792B1 Novel ligand of g-protein-conjugated receptor protein and use thereof
11/03/2010EP1703902B1 Memantine for the treatment of mild-to-moderate alzheimer's disease
11/03/2010EP1702625B1 Medicine containing genetically modified antibody against chemokine receptor ccr4
11/03/2010EP1696825B1 Use of alginate matrices to control cell growth
11/03/2010EP1556080B1 Furin inhibitors for use in the treatment of fibrosis and scarring
11/03/2010EP1499742B1 Nad(p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
11/03/2010EP1404302B1 Pharmaceutical compositions comprising adsorbates of amorphous drug
11/03/2010CN1958074B Injectable block copolymer hydrogel of temperature sensibility(epsi - caprolactone - glycolide)- polyethyleneglycol
11/03/2010CN1812812B Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis
11/03/2010CN1738634B Extract of stephaniae sinica diels and methods of using the same
11/03/2010CN101878297A Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
11/03/2010CN101878039A Antidiarrhetic composition, product containing the same and method of preventing diarrhea
11/03/2010CN101878030A Compositions and methods for treating immunological and inflammatory diseases and disorders
11/03/2010CN101874803A Slow-release injection containing vasoinhibitor and synergistic agent thereof
11/03/2010CN101874784A Crystal separating drug sustained-release microspherule and preparation method thereof
11/03/2010CN101130081B Use of PNAS-4 gene in preparing antineoplastic and antineoplastic auxiliary medicament
11/03/2010CN101029336B Reagent kit for predicting serotonin re-uptake inhibitor medicine effect
11/02/2010US7825219 Binding protein; therapy for bone tumors
11/02/2010US7825124 Indolylmaleimide derivatives
11/02/2010US7825109 Compound capable of binding S1P receptor and pharmaceutical use thereof
11/02/2010US7825094 the sensitivity of cells typical of various proliferative disorders to the ansamycin CNF-101 ("17-AAG") is proportional to the HER-2 levels in those cells
11/02/2010US7825080 Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant
11/02/2010US7824851 With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region
11/02/2010US7824850 Methods of protein destabilization and uses thereof
11/02/2010US7824706 synergistic efficacy; polar lipid supplement, a soluble fiber, and a nutricine such as threonine
11/02/2010US7824696 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups
11/02/2010US7824695 recombinant proteins comprise cell recognition moiety that binds alpha 2 macroglobulin receptor, and bioactive moiety (pseudomonas exotoxin), which mediates systemic effect, does not function as immunogen and does not have ADP ribosylating activity
11/02/2010US7824688 Glucan-based vaccines
11/02/2010US7824686 Vaccines with enhanced immune response and methods for their preparation
11/02/2010US7824683 Methods for augmenting an immune response using anti-CD40 antibodies
11/02/2010US7824674 An antibody for treating Crohn's disease and ulcerative colitis, inhibit the transduction of biological activity of cytokine, B-cell differentiation factors
11/02/2010US7824669 administering a composition comprising a GM-CSF cysteine mutein of SEQ ID NO:8, wherein a cysteine residue is substituted for an amino acid selected from the group consisting of A1, A3, S5, S7, N27, T32, A33, E51, R67, S69, E93, T94, T98, Q99, T102, E123, V125, Q126, and E127
11/02/2010CA2446639C Composition for the prevention of addiction in pain management
11/02/2010CA2437481C The use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
11/02/2010CA2436361C Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent
11/02/2010CA2417432C Modified polypeptides stabilized in a desired conformation and methods for producing same
11/02/2010CA2407466C Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
11/02/2010CA2393523C Combination of cyamemazine and an atypical neuroleptic
11/02/2010CA2383293C Anti-infective compositions for treating disordered tissue such as cold sores
11/02/2010CA2360252C Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
11/02/2010CA2337422C Preventing airway mucus production by administration of egf-r antagonists
11/02/2010CA2281049C Water-soluble pharmaceutical composition in an ionic complex and the use thereof
1 ... 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 ... 1151